Background: Sacubitril/valsartan decreased the risk of sudden cardiac death (SCD) in
patients suffering from heart failure with reduced ejection fraction (HFrEF). However, long …

Exacerbation of chronic heart failure (HF) is the most common cause of hospitalization in
adults, which is associated with high morbidity and mortality rates, mainly due to HF …

Aims Conflicting results have been reported in the literature on the potential antiarrhythmic
effect of sacubitril/valsartan in heart failure patients with reduced ejection fraction (HFrEF) …

The aim of this study was to assess whether angiotensin receptor/neprilysin inhibitor (ARNI)
decreases ventricular arrhythmic burden compared to angiotensin-converting enzyme …

Aims Sacubitril/valsartan significantly reduced heart failure (HF) hospitalization and
cardiovascular mortality in a randomized controlled trial. However, little is known about real …

Aims Sudden death is a leading cause of mortality in heart failure with reduced ejection
fraction (HFrEF). In PARADIGM‐HF, sacubitril/valsartan reduced the incidence of sudden …

Aims This sub-study deriving from a multicentre Italian register [Deformation Imaging by
Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic …

Background: Sacubitril/valsartan reduced heart failure (HF)-admissions and cardiovascular
mortality in the PARADIGM-HF-trial. However, real-world patients are often frailer and less …

Sacubitril/valsartan reduces heart failure (HF)-related hospitalizations and cardiovascular
mortality in PARADIGM-HF and has become a foundational treatment for HF with reduced …

Purpose Patients affected by heart failure with reduced ejection fraction (HFrEF) receive
clinical and functional beneficial effects from treatment with sacubitril/valsartan. However …